Intimation/Disclosure of events under Regulation 30 of the Securities and Exchange Board of India (LODR) Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
On August 5, 2025, the Board of Welcure Drugs & Pharmaceuticals approved the appointment of Mr. Ravi Thakor (DIN: 11210729) as an Additional Director, designated as Non-Executive (Independent/Non-Independent — the document contains a minor inconsistency between the body and Annexure I). The appointment takes effect from August 5, 2025 and is subject to shareholder approval at a general meeting. Mr. Thakor brings experience in management, strategic planning, and organisational growth. He is not related to any existing director and is not debarred by SEBI or any authority from holding a directorship.
This is a routine board-level addition with no immediate material impact on financials or operations. Shareholders will get to vote on his appointment at the next general meeting; until then he holds the additional director position. Investors may watch for the shareholder approval outcome.